

ABRAHAM WILLIAM
Form 4
June 02, 2009

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
ABRAHAM WILLIAM

2. Issuer Name and Ticker or Trading Symbol
CONMED CORP [CNMD]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)
**C/O CONMED CORP, 525
FRENCH ROAD**

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2009

____ Director _____ 10% Owner
 Officer (give title below) _____ Other (specify below)
Senior Vice President

(Street)
UTICA, NY 13502

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				(A) or (D) Price			
Common Stock	06/01/2009		M	200 A \$ 0	50,774	D	
Common Stock	06/01/2009		F	75 D \$ 0	50,699	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Edgar Filing: ABRAHAM WILLIAM - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	Amount or Number of Shares
Rsus (restricted Stock Units)	\$ 0	06/01/2009		M	200	<u>(1)</u> 06/01/2018	Common Stock	200
Rsus (restricted Stock Units)	\$ 0	06/01/2009		A	2,000	<u>(2)</u> 06/01/2019	Common Stock	2,000
Sars (Stock Appreciation Rights)	\$ 16.46	06/01/2009		A	5,000	<u>(3)</u> 06/01/2019	Common Stock	5,000

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
ABRAHAM WILLIAM C/O CONMED CORP 525 FRENCH ROAD UTICA, NY 13502			Senior Vice President	

Signatures

Daniel S. Jonas for William Abraham by Power of Attorney 06/02/2009

**Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value \$0.01 per share of (1) ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2006 Stock Incentive Plan, with the RSUs generally vesting over a five year period with the first 20% of the RSU's vesting one year after the grant date.

Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value \$0.01 per share of (2) ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 1999 Stock Incentive Plan, with the RSUs generally vesting over a five year period with the first 20% of the RSU's vesting one year after the grant date.

Edgar Filing: ABRAHAM WILLIAM - Form 4

- (3) The stock appreciation rights ("SARs") were granted under the Company's 1999 Stock Incentive Plan and generally vest in equal amounts over a five year period.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number. t: -0.5in">

- (d) During the last five years, the Reporting Person has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors);

- (e) During the last five years, the Reporting Person has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result thereof were or are subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities law or finding any violation with respect to such laws; and

- (f) The Reporting Person is a citizen of the United States.

Item 3. Source or Amount of Funds or Other Consideration.

All funds used to purchase common stock were assets of the Reporting Person or respective investment advisory clients. In addition, none of the funds used to purchase the common stocks were provided through borrowings of any nature.

Item 4. Purpose of Transaction.

The Reporting Person acquired the common stock for investment purposes in consideration of the future prospects of the Issuer as an effective long-term investment. The Reporting Persons may acquire additional shares of common stock, or dispose of the shares of common stock, from time to time, in open market or privately negotiated transactions. Except as set forth above, the Reporting Person has no plans or proposals with respect to any of the matters set forth in paragraphs (a) through (j) of Item 4 of Schedule 13D.

Item 5. Interest in Securities of the Issuer.

- (a) The aggregate number of common stock to which this Schedule 13D relates is 1,001,180 common stock representing 16.32% of the 6,133,659 shares outstanding as reported by the issuer as of June 30, 2018.

- (b) With respect to the shares of common stock owned individually, the Reporting Person beneficially owns with sole power to vote and dispose of 498,348 shares of common stock. With respect to the Accounts, the Reporting Person beneficially owns, with shared power to vote and/or dispose of 502,832 shares of common stock.

Explanation of Responses:

Prior to November 15, 2018 advisory clients owned 604,826 shares of common stock. Prior to November 15, 2018 the Reporting Person owned 473,085 shares of common stock. On November 15, 2018 through the open market the advisory clients sold 4,916 shares of common stock at \$5.7465 per share. On December 13, 2018 through the open market the advisory clients sold 785 shares of common stock at \$5.2646 per share. On December 17, 2018 through the open market the advisory clients sold 13,417 shares of common stock at \$5.1963 per share. On December 18, 2018 through the open market the advisory clients sold 3,114 shares of common stock at \$5.213 per share. On December 19, 2018 through the open market the advisory clients sold 11,838 shares of common stock at \$5.1112 per share. On December 20, 2018 through the open market the advisory clients sold 8,700 shares of common stock at \$4.98 per share. On December 21, 2018 through the open market the advisory clients sold 10,000 shares of common stock at \$4.9008 per share. On December 26, 2018 through the open market the advisory clients sold 20,000 shares of common stock at \$4.8802 per share. On December 27, 2018 through the open market the advisory clients sold 26,434 shares of common stock at 4.8709. On December 28, 2018 through dividend reinvestment the Reporting Person purchased 9,263 shares of common stock at \$5.0023 per share. On December 31, 2018 through dividend reinvestment the advisory clients purchased a total of 2,470 shares of common stock at the price of \$5.2883 per share. On December 31, 2018 through the open market the advisory clients sold 5,260 shares of common stock at \$4.96 per share. On January 2, 2019 through the open market, the Reporting person purchased 5,600 shares of common stock at \$4.9703 per share. On January 3, 2019 through the open market, the Reporting person purchased 10,400 shares of common stock at \$4.99 per share.

(c) The owner of each of the Accounts individually has the right to receive and the power to direct the receipt of (d)dividends from, or proceeds from the sale of, the shares of common stock. To date no owner of an Account holds more than 5% of the Issuer's common shares.

(e) Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

Except for the investment advisory agreements between Thomas J. Herzfeld Advisors, Inc. and the owners of the Accounts, there are no contracts, arrangements, understandings or relationships (legal or otherwise) between the Reporting Person and any other person with respect to any securities of the Issuer.

Item 7. Material to Be Filed as Exhibits.

None.

CUSIP No. 42804T106 13D Page 4 of 4 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Thomas J. Herzfeld Advisors, Inc.

/s/ Thomas J. Herzfeld
Thomas J. Herzfeld
Chairman

January 7, 2019
Date